- Home
- THRY vs ABOS Comparison
THRY vs ABOS Comparison
Compare THRY & ABOS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | THRY | ABOS |
|---|---|---|
| Founded | 2012 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 179.6M | 197.9M |
| IPO Year | 2020 | 2021 |
Fundamental Metrics
Financial Performance| Metric | THRY | ABOS |
|---|---|---|
| Price | $1.58 | $2.33 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 2 |
| Target Price | ★ $9.33 | $8.00 |
| AVG Volume (30 Days) | ★ 674.5K | 358.3K |
| Earning Date | 04-30-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 100.50 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $785,015,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.60 | $1.50 |
| 52 Week High | $12.57 | $3.60 |
Technical Indicators
Market Signals| Indicator | THRY | ABOS |
|---|---|---|
| Relative Strength Index (RSI) | 30.47 | 37.61 |
| Support Level | N/A | $2.13 |
| Resistance Level | $2.17 | $2.42 |
| Average True Range (ATR) | 0.13 | 0.18 |
| MACD | 0.01 | -0.07 |
| Stochastic Oscillator | 3.23 | 16.36 |
Price Performance
Historical ComparisonAbout THRY Thryv Holdings Inc.
Thryv Holdings Inc is dedicated to supporting local, independent service-based businesses and emerging franchises by providing a cloud-based software platform, and marketing solutions to entrepreneurs. The group are provider of SaaS all-in-one small business management software in addition to providing print and digital marketing solutions to SMBs. Its solutions enable small and medium-sized business clients to attract and generate new business leads, manage their customer relationships efficiently with artificial intelligence (AI) tools and automation. The group has two business segments; Thryv SaaS deriving maximum revenue and Thryv Marketing Services.
About ABOS Acumen Pharmaceuticals Inc.
Acumen Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing a novel disease-modifying approach to target what it believes to be a key underlying cause of Alzheimer's disease. The company's drug candidate, ACU193, is a subclass monoclonal antibody that selectively targets amyloid-beta oligomers. The product pipelines include: ALTITUDE-AD; and INTERCEPT-AD.